Version history

{
  "session_id": "sess_SDA-BIOMNI-PROTEOMI-c4a33049",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "mini-max",
  "action": "critique",
  "content": "\n\n# Critical Evaluation of AD Proteomic Hypotheses\n\n---\n\n## Hypothesis 1: SNAP91/SYT1 Synaptic Vesicle Trafficking Proteins\n\n### Weaknesses\n\n1. **Cell-type specificity confounds**: Whole-tissue homogenates cannot distinguish neuronal synaptic loss from layer-specific neurodegeneration. AD prefrontal cortex shows laminar-specific vulnerability—measurements may reflect neuronal dropout rather than coordinated synaptic proteome change.\n\n2. **CSF biomarker validity questionable**: SNAP91 and SYT1 are **intracellular** proteins. The \"proportional shedding\" assumption lacks mechanistic support—intracellular proteins are typically degraded *in situ* during synapse loss, not released into CSF. Compare to NfL (axonal) or neurogranin (postsynaptic cytosolic)—these have established extracellular release mechanisms.\n\n3. **Post-mortem artifact**: 40-60% reduction in prefrontal cortex requires rigorous PMI matching. Protein degradation in brains with long PMI (>24h) may artifactually inflate apparent AD-specific reductions.\n\n4. **Non-AD specificity**: Synaptic protein reductions are documented in frontotemporal dementia, Lewy body dementia, and vascular dementia—limiting diagnostic specificity.\n\n5. **Temporal trajectory ambiguity**: The hypothesis assumes early synaptic dysfunction, but cross-sectional cohort data cannot resolve whether these proteins are reduced *before* cognitive symptoms or only at end-stage.\n\n### Counter-Evidence\n\n- Some longitudinal studies show synaptic protein **upregulation** in early compensatory phases before decline\n- SNAP91 involvement in clathrin-mediated endocytosis means changes could reflect endosomal pathway dysfunction unrelated to synaptic loss\n- Existing CSF biomarker literature (e.g., neurogranin as synaptic marker) suggests alternate candidates have stronger validation\n\n### Falsification Experiments\n\n1. **Perform IP-MS on matched CSF samples** from same cohorts—directly test whether SNAP91/SYT1 are detectable and AD-discriminatory at protein level in CSF (not inferred from brain tissue)\n2. **Single-nucleus proteomics** from flash-frozen tissue to normalize for neuronal vs. non-neuronal cell populations\n3. **Cohort comparison**: Test these proteins in non-AD neurodegenerative cohorts (PSP, CBD, FTD) to establish specificity\n4. **In vitro assay**: Expose human iPSC-derived neurons to Aβ oligomers—determine if reduced SNAP91/SYT1 reflects direct Aβ toxicity or merely neuronal death\n\n### Revised Confidence: **0.52**\n\n---\n\n## Hypothesis 2: GFAP/YKL-40",
  "tokens_used": "628"
}